These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 25216821)

  • 21. A Nonparametric Pharmacokinetic Approach to Determine the Optimal Dosing Regimen for 30-Minute and 3-Hour Meropenem Infusions in Critically Ill Patients.
    Mathew SK; Mathew BS; Neely MN; Naik GS; Prabha R; Jacob GG; K S; Fleming DH
    Ther Drug Monit; 2016 Oct; 38(5):593-9. PubMed ID: 27454665
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.
    Lee LS; Kinzig-Schippers M; Nafziger AN; Ma L; Sörgel F; Jones RN; Drusano GL; Bertino JS
    Diagn Microbiol Infect Dis; 2010 Nov; 68(3):251-8. PubMed ID: 20851549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia].
    Cousson J; Floch T; Vernet-Garnier V; Appriou M; Petit JS; Jovenin N; Lamiable D; Hoizey G
    Pathol Biol (Paris); 2005; 53(8-9):546-50. PubMed ID: 16023303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection.
    De Jongh R; Hens R; Basma V; Mouton JW; Tulkens PM; Carryn S
    J Antimicrob Chemother; 2008 Feb; 61(2):382-8. PubMed ID: 18070831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects.
    Wenzler E; Gotfried MH; Loutit JS; Durso S; Griffith DC; Dudley MN; Rodvold KA
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7232-9. PubMed ID: 26349830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy?
    Varghese JM; Jarrett P; Wallis SC; Boots RJ; Kirkpatrick CM; Lipman J; Roberts JA
    J Antimicrob Chemother; 2015 Feb; 70(2):528-33. PubMed ID: 25336163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation.
    Lodise TP; Nau R; Kinzig M; Drusano GL; Jones RN; Sörgel F
    J Antimicrob Chemother; 2007 Nov; 60(5):1038-44. PubMed ID: 17785282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility.
    Roberts JA; Lipman J
    Crit Care Med; 2013 Feb; 41(2):489-95. PubMed ID: 23263583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem.
    Conte JE; Golden JA; Kelley MG; Zurlinden E
    Int J Antimicrob Agents; 2005 Dec; 26(6):449-56. PubMed ID: 16280244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meropenem dosing requirements against Enterobacteriaceae in critically ill patients: influence of renal function, geographical area and presence of extended-spectrum β-lactamases.
    Isla A; Canut A; Arribas J; Asín-Prieto E; Rodríguez-Gascón A
    Eur J Clin Microbiol Infect Dis; 2016 Mar; 35(3):511-9. PubMed ID: 26782093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem.
    So W; Crandon JL; Hamada Y; Nicolau DP
    J Antimicrob Chemother; 2016 Feb; 71(2):428-37. PubMed ID: 26559690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.
    Krueger WA; Bulitta J; Kinzig-Schippers M; Landersdorfer C; Holzgrabe U; Naber KG; Drusano GL; Sörgel F
    Antimicrob Agents Chemother; 2005 May; 49(5):1881-9. PubMed ID: 15855510
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostatic penetration of meropenem in humans, and dosage considerations for prostatitis based on a site-specific pharmacokinetic/pharmacodynamic evaluation.
    Nishikawa G; Ikawa K; Nakamura K; Yamada Y; Zennami K; Mitsui K; Narushima M; Ikeda K; Morikawa N; Sumitomo M
    Int J Antimicrob Agents; 2013 Mar; 41(3):267-71. PubMed ID: 23313536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients.
    Kees MG; Minichmayr IK; Moritz S; Beck S; Wicha SG; Kees F; Kloft C; Steinke T
    J Clin Pharmacol; 2016 Mar; 56(3):307-15. PubMed ID: 26222202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients?
    Alobaid AS; Brinkmann A; Frey OR; Roehr AC; Luque S; Grau S; Wong G; Abdul-Aziz MH; Roberts MS; Lipman J; Roberts JA
    J Antimicrob Chemother; 2016 Mar; 71(3):696-702. PubMed ID: 26702922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration.
    De Pascale G; Fortuna S; Tumbarello M; Cutuli SL; Vallecoccia M; Spanu T; Bello G; Montini L; Pennisi MA; Navarra P; Antonelli M
    Intensive Care Med; 2015 Jan; 41(1):103-10. PubMed ID: 25413377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extended versus bolus infusion of meropenem and piperacillin: a pharmacokinetic analysis.
    De Waele J; Carlier M; Hoste E; Depuydt P; Decruyenaere J; Wallis SC; Lipman J; Roberts JA
    Minerva Anestesiol; 2014 Dec; 80(12):1302-9. PubMed ID: 24762706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia.
    Lodise TP; Sorgel F; Melnick D; Mason B; Kinzig M; Drusano GL
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1606-10. PubMed ID: 21300830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimising meropenem dosing in critically ill Australian Indigenous patients with severe sepsis.
    Tsai D; Stewart P; Goud R; Gourley S; Hewagama S; Krishnaswamy S; Wallis SC; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2016 Nov; 48(5):542-546. PubMed ID: 27771187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units.
    Jaruratanasirikul S; Thengyai S; Wongpoowarak W; Wattanavijitkul T; Tangkitwanitjaroen K; Sukarnjanaset W; Jullangkoon M; Samaeng M
    Antimicrob Agents Chemother; 2015; 59(6):2995-3001. PubMed ID: 25753628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.